Abstract
Objectives
The objective of this systematic review is to identify and summarise studies which examine epigenetic biomarkers in patients with Barrett’s oesophagus (BO) and their association with progression to oesophageal adenocarcinoma (OADC). BO is a precursor lesion for oesophageal adenocarcinoma OADC. There is no clinical test to predict patients who are likely to progress to OADC. An epigenetic biomarker could predict patients who are at high risk of progression from BO to OADC which could facilitate earlier diagnosis and spare those unlikely to develop cancer from regular invasive surveillance endoscopy.
Setting
A systematic search was conducted of the following databases: MEDLINE, MEDLINE in Process, EMBASE, Cochrane Central, ISI Conference Proceedings Citation Index and the British Library’s ZETOC. Studies were conducted in secondary and tertiary care settings.
Participants
All studies measuring epigenetic change in patients over 18 years old who progressed from NDBO to OADC were included. Genetic, in vitro and studies which did not measure progression in the same patient cohort were excluded. Study inclusion and risk of bias of individual eligible studies was assessed in duplicate by two reviewers using a modified Quality in Prognostic Studies (QUIPS) tool.
Results
14 studies met the inclusion criteria. 42 epigenetic markers were identified, 5 studies developed models aiming to predict progression to OADC.
Conclusions
The evidence from this systematic review is suggestive of a role for p16 as an epigenetic biomarker for the progression of BO to OADC.
PROSPERO systematic review registration number CRD42016038654.
The objective of this systematic review is to identify and summarise studies which examine epigenetic biomarkers in patients with Barrett’s oesophagus (BO) and their association with progression to oesophageal adenocarcinoma (OADC). BO is a precursor lesion for oesophageal adenocarcinoma OADC. There is no clinical test to predict patients who are likely to progress to OADC. An epigenetic biomarker could predict patients who are at high risk of progression from BO to OADC which could facilitate earlier diagnosis and spare those unlikely to develop cancer from regular invasive surveillance endoscopy.
Setting
A systematic search was conducted of the following databases: MEDLINE, MEDLINE in Process, EMBASE, Cochrane Central, ISI Conference Proceedings Citation Index and the British Library’s ZETOC. Studies were conducted in secondary and tertiary care settings.
Participants
All studies measuring epigenetic change in patients over 18 years old who progressed from NDBO to OADC were included. Genetic, in vitro and studies which did not measure progression in the same patient cohort were excluded. Study inclusion and risk of bias of individual eligible studies was assessed in duplicate by two reviewers using a modified Quality in Prognostic Studies (QUIPS) tool.
Results
14 studies met the inclusion criteria. 42 epigenetic markers were identified, 5 studies developed models aiming to predict progression to OADC.
Conclusions
The evidence from this systematic review is suggestive of a role for p16 as an epigenetic biomarker for the progression of BO to OADC.
PROSPERO systematic review registration number CRD42016038654.
Original language | English |
---|---|
Article number | e020427 |
Journal | BMJ open |
Volume | 8 |
DOIs | |
Publication status | Published - 30 Jun 2018 |